65 results about "Hexosamines" patented technology

A topical skin rejuvenation preparation to relieve wrinkles, increase the skin's natural production of hyaluronic acid, reverse the lack of suppleness, hydrate from within, erase spider veins, reduce varicose veins, lighten aging dark blotches (“liver spots” / Lentigos, Senile Lentigines), decrease acne, and reduce under eye puffiness includes Glucosamine (2-amino-2-deoxy-alpha-D-glucose), a hexosamine (6 carbon amino sugar), including its derivative and precursor compounds: Glucosamine Sulfate, Glucosamine Hydrochloride, Glucose-6-Phosphate, Acetyl Glucosamine, Fructose-6-phosphate, Glucosamine-6-Phosphate, to increase production of Hyaluronic acid and collagen from Glucosamine Sulfate, its precursors and derivatives and to increase skin muscle tone by Dimethylaminoethanol (DMAE) while over coming deficiency it creates in each cell's production of PhosphatidylCholine, whose deficiency damages cell membranes, as well as mitochondrial and lysosome membranes.

Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic acid, vitamin B12 and a serotonin inhibitor. Such treatment prevents, reduces or eliminates SVFS in patients receiving as much as 300-3000 mg / day of niacin therapeutically, whether administered prior to, or along with, an anti-SVFS composition.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containg one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil / extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

Nucleic acids comprising β-glucosaminyloxy-5-methylcytosine; compositions, kits and methods of producing the nucleic acids using a glycosyltransferase; and methods of using the nucleic acids are described.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil / extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

Disclosed are compositions and methods related to nucleic acid constructs containing a HexB encoding element and a HexA encoding element. These constructs can be used in the treatment of Tay-Sachs and Sandoff disease.

The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and / or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and / or hexosamine, with subsituents containing a ONO2 ? group.

Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined kernel olive oil that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

A composition for treating cancer is provided. The composition is a hexosaminidase covalently attached to a cancer cell targeting ligand and improves selectively of the hexosaminidase for tumor cells. In certain embodiments, the hexosaminidase is alternately chitinase (N-acetyl-glucosaminohydrolase), chitosanase, or N-acetyl-hexosaminidase and the targeting ligand is either a monoclonal antibody, an antibody fragment immunospecific to a tumor cell or cancer cell antigen, epidermal growth factor (EGF), fibroblast growth factor (FGF), transferrin, or folic acid. Also provided is a method for treating cancerous tumors comprising administering the composition to a patient that has a cancerous tumor.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.

The invention discloses application of a compound for efficient inhibition of chitinase OfChi-h and hexosaminidase OfHex1 activity, and relates to application of a compound phlegmacin B1 and its derivatives in inhibiting chitinase OfChi-h and hexosaminidase OfHex1 activity. The used final concentration is not less than 13ppm, under the concentration, the measured inhibition rates are 90.4% and 71.4% respectively, and inhibition constants Ki are 5.5 microM and 26 microM respectively. The invention proves that the compound phlegmacin B1 has good application prospect in the prevention and control of agricultural pests, especially in prevention and control of lepidoptera insects.

The invention relates to a chondroitin sulfate extraction method, and especially relates to a method for extracting chondroitin sulfate from sturgeon bones through a diluted alkali-enzymatic hydrolysis technology. The method is characterized in that alkali liquid extraction and salt precipitation are carried out to remove proteins, and the method concretely comprises the following steps: adding a NaOH solution with the concentration of 3% to dried sturgeon cartilages according to a solid-to-liquid ratio of 1:6 (g / ml), extracting at 35 DEG C for 2 h, taking the obtained supernatant, adding 3% (g / ml) of NaCl, allowing the obtained solution to stand at 90 DEG C for 20 min, and filtering the solution; and carrying out enzymatic hydrolysis by using pancreatin. The extraction method greatly improves the content of an effective component hexosamine in the above product. The chondroitin sulfate (CS) is connected with serine residues of protein molecules through oligomeric glucosides, so the CS released in the diluted alkali-enzymatic hydrolysistechnology may be still connected with a plurality of amino acid residues or polypeptides due to the certain specificity of enzyme hydrolysis peptide chains. The extraction method reduces the use amount of protease through setting the heating salt precipitation step in order to reduce the production cost, so the problem of slight high nitrogen content of the above product is solved to a certain degree.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oillextract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil / extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

The present invention provides a composition which includes elicitor compounds selected from the group consisting of: (N,N′diacetylhexobiose)n; (N,N′diacetylhexobiose)n having one or more associated amino acid residues, wherein the amino acid residues are valine or ornthine; (N,N′diacetylhexosamine)n having an associated (dihexobiose)n; (N,N′diacetylhexosamine)n having an associated (dihexobiose)n and one or more associated amino acid residues, wherein the amino acid residues are valine or ornithine; or combinations thereof. The (N,N′diacetylhexobiose)n and (N,N′diacetylhexosamine)n comprise N-acetylglucosamine or other amino hexosamines, while the (N,N′diacetylhexobiose)n and (dihexobiose)n are any D-hexoaldose or N-acetylamino derivative of D-hexoaldoses. In this aspect of the present invention, n=1 to 5 and the compounds are all 3 kDa or less. Also provided are a method for increasing the rate of fungal growth, a method for increasing extracellular fungal enzyme production, a method for increasing biological control of plant and animal diseases, a method for increasing a method for increasing resistance of plants to diseases, and a method of alleviating pain and increasing resistance to, or recovery from, diseases in animals, using the composition of the present invention.

The invention discloses an analysis method of disaccharides containing uronic acid based on reductive amine derivatization. The analysis method comprises the following specific steps: extracting polysaccharides in animal tissue and collecting polysaccharides containing uronic acid; carrying out acid hydrolysis to obtain disaccharide products; adding a reduction amine reagent solution, preparing reduction amine derivatives of disaccharides of polysaccharides containing uronic acid, detecting by using a high performance liquid chromatography-multistage mass spectrometry, and indirectly achieving qualitative analysis on the polysaccharides containing uronic acid. The invention also provides a preparation method of the disaccharides containing uronic acid based on reductive amine derivatization. The method is suitable for analyzing and preparing disaccharides of two types of hexuronic acid-hexosamine and hexuronic acid-hexose; acid degradation is adopted; compare with enzymatic degradation, acid hydrolyzation is low in cost and simple to operate, and has degradation effects on various polysaccharides; ammonium hydroxide is used for replacing common NaOH; ammonium hydroxide is volatilizable, is easy to remove, and can facilitate the mass spectrometry analysis in the later period.

The invention discloses sturgeon compound powder, sturgeon bone wine and application. The sturgeon compound powder is prepared from sturgeon meat and soft bone as raw materials through enzymolysis by using a complex enzyme, separation by using an ultrafiltration membrane separator, macroreticular resin (HPD series) and activated carbon and through spray drying. The sturgeon compound powder is capable of effectively clearing free radicals and improving organism immunity, and has wide application prospects in fields of food, medicines and cosmetics. The sturgeon compound powder and base wine are blended to form the sturgeon bone wine, and the sturgeon bone wine has not only the specific fresh taste of sturgeon, but also sturgeon protein and hexosamine, is relatively rich in nutrition, can do no harm to livers, has a function of protecting the livers, and can replenish chondroitin sulfate to human body joints when being taken for a long time.

The invention provides a method for quantitative determination of uronic acid-containing polysaccharide. The method comprises the following specific steps of preparing a uronic acid-containing polysaccharide standard substance solution from trifluoroacetic acid, wherein the uronic acid-containing polysaccharide is the polysaccharide of which a main chain is formed by a hexuronic acid-hexosamine or hexuronic acid-hexose disaccharide repeated disaccharide fragment; carrying out acid hydrolysis and deacidification on a standard substance to obtain a to-be-tested sample acid hydrolysis residue; dissolving a standard sample acid hydrolysis residue, and carrying out analysis by using a high-performance liquid chromatography-tandem triple quadrupole mass spectrometer to obtain a multi-response monitoring chromatogram and a standard curve; processing and detecting the to-be-tested sample acid hydrolysis residue by adopting the same method; and identifying the variety of the uronic acid-containing polysaccharide and obtaining the content of the uronic acid-containing polysaccharide in the to-be-tested sample. The method is simple in operation step, low in reagent price and relatively short in elapsed time, and polysaccharide formed by repeated disaccharide fragments of uronic acid and hexosamine or hexose can be accurately quantified at the same time.

Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric fraction, serotonin, post-menopause, alcohol or monosodium glutamate, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, administered alone or together with an anti-superficial vasodilation dose of one or more of a non-bovine sulfated proteoglycan, a D-hexosamine sulfate, a serotonin inhibitor, willow bark extract and an olive kernel extract. As much as 100% protection against niacin flush can be achieved by luteolin and quercetin alone. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and / or hexosamine, containing nitro groups -ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polyssacchrides essentially formed of units of uronic acid and / or hexosamine, with subsituents containing a ONO<custom-character file="US20030181417A1-20030925-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >2? group.